-

Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO"). Poseida is a clinical-stage biopharmaceutical company that develops therapeutics for patients with high unmet medical needs.

If you have suffered a loss due to Poseida Therapeutics, Inc.'s misconduct, click here.

Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share. On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient's death. On this news, Poseida's stock fell 30.31%, to close at $9.06 on August 18, 2020.

Poseida Therapeutics, Inc. (PSTX) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Poseida settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:PSTX
Release Versions
English
$Cashtags
$GNUS
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Shareholder Notice: Robbins LLP Informs Investors of the Lucid Group, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lucid Group, Inc. (NASDAQ: LCID) securities between February 25, 2026 and April 13, 2026. Lucid is a technology company that designs, develops, manufactures, and sells electric vehicles (“EVs”), EV powertrains, and battery systems.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Alleg...

Investor Notice: Robbins LLP Informs Investors of the Calix, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Calix, Inc. (NYSE: CALX) securities between January 28, 2026 and April 21, 2026. Calix engages in the provision of cloud and software platforms, and systems and services.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Calix,...

Investor Notice: Robbins LLP Informs Investors of the Zoetis Inc. Class Action  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026. Zoetis is an animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a...
Back to Newsroom